AirMini™ – Go anywhere with the world’s smallest CPAP device*

We’re delighted to have launched a new CPAP device. The AirMini is the world’s smallest CPAP therapy solution (as of 4th April 2017). It’s portable, smart and proven and we think it’s going to be a game-changer for your sleep apnoea and your lifestyle and it’s now available to buy. Let’s meet this mini marvel.

It’s hard not to be bowled over by the size of the AirMini. See our video to watch the reaction when some lucky users got to see it for the first time. The AirMini measures 13.6 cm in length – that’s a fraction less than an iPhone 6s – and weighs only 300 grams. Wow!

The AirMini offers the high quality CPAP experience you’d expect from ResMed while its revolutionary size opens up a world of possibilities in terms of freedom, travel and ease of use. It fits in your handbag when you’re on an overnight stay and gives you the chance to get some proper sleep on a long-haul flight.

Now you can enjoy the benefits of sleep apnoea therapy whether you’re camping in the wilds or pampering yourself in 5-star style: wherever you want to go and however you travel, the portable AirMini is your perfect companion. You can find it at ResMed’s official online shop.

High tech, high performance
When you experience the AirMini’s size for the first time, you might wonder what the catch is. How can something so small and portable offer the same performance as a normal bedside CPAP device? Amazingly, it can, because the AirMini is a comforting blend of proven technologies and clever new space-saving tricks. For example, with the AirMini, you can enjoy the easy-breathing benefits of humidification thanks to advanced, waterless humidification technology that mimics the body’s natural humidification processes. More about this soon.

The algorithms that deliver your sleep apnoea therapy are tried and tested: the AirMini is made by ResMed, a global leader in respiratory devices, and it delivers the same trusted performance as their already proven and popular bedside CPAP devices1,2,3,4,5,6.

To shrink that performance into a mini package, ResMed’s talented engineers developed ActiveAir™, an innovative new venting system that’s so efficient that therapy can be delivered by a motor that is 45% smaller than the motor in a bedside CPAP device. That clever invention also means the AirMini can make the most of ResMed’s expertise in mask design: your new travel companion is compatible with the AirFit™ N20 nasal masks, F20 full-face masks and P10 pillows masks.

Smart and engaging
Being smart is another thing that helps the AirMini stay small. The device features simple, one-button operation and a seamless Bluetooth connection to an AirMini app on your smartphone. That AirMini smartphone app unlocks a rich, engaging therapy experience. It enables you to manage your comfort options (including favourites such as AutoRamp and Smart Start & Stop) and monitor your sleep. Later this year it will even be able to offer you personalised sleep apnoea coaching and encouragement.

Excited by the freedom and health benefits you could gain with the small, smart and proven AirMini? Contact one of our clinics in London and Oxfordshire for more information or start shopping!

*As of 4th April 2017

1 Netzel et al. APAP device technology and correlation with patient compliance. Somnologie – Schlafforschung und Schlafmedizin 2014; DOI: 10.1007/s11818-014-0662-0.
2 Isetta et al. Comparative assessment of several automatic CPAP devices responses: a bench test study. ERJ Open Res 2015;1:00031-2015.
3 Zhu et al. All APAPs are not equivalent for the treatment of sleep disordered breathing: a bench evaluation of eleven commercially available devices. J Clin Sleep Med 2015 11(7):725-34.
4 Isetta et al. Novel Approach to Simulate Sleep Apnea Patients for Evaluation Positive Pressure Therapy Devices. PLoS ONE 11(3): e0151530.doi:10.1371/journal.pone.0151530.
5 ResMed AirFit N20 internal global fitting study of 159 existing ResMed patients, conducted 12/11/2015 ; ID A3697629.
6 ResMed AirFit F20 internal fitting study of 27 ResMed and non-ResMed patients, conducted between 30/03/2016 – 04/04/2016. Preliminary patient study – data on file; ID A3751086.